Table 1 Patient characteristics according to subgroup of weight variation during chemotherapy. (p represents the p-value based on ANOVA, Welch’s ANOVA, or Kruskal-Wallis test for continuous data, and the Chi-squared test for categorical data)

n

n

n

n

Median age (range) — yrs

109

48 (25–74)

32

48 (26–62)

66

49 (25–74)

11

61 (40–70)

0.024

 At baseline

109

66.5 (15.2)

32

60.2 (8.9)

66

67.1 (14.8)

11

81.5 (21.5)

0.01

 At the end of chemotherapy

109

67.5 (14)

32

65.3 (9.8)

66

67.5 (14.6)

11

73.8 (19.6)

0.686

 At the end of Herceptin®

109

67.1 (14.5)

32

63.9 (9.7)

61

67.6 (15.1)

10

73.8 (21.3)

0.212

 At baseline

109

25.1 (5.7)

32

22.6 (3.7)

66

25.3 (5.2)

11

31.2 (8.4)

0.005

 At the end of chemotherapy

109

25.5 (5.3)

32

24.5 (4.1)

66

25.5 (5.2)

11

28.3 (7.8)

0.579

 At the end of Herceptin®

109

25.3 (5.5)

32

24.0 (4.1)

61

25.5 (5.4)

10

28.5 (8.5)

0.148

0.203

 Yes

52

47.7

19

59.4

30

45.5

3

27.3

 No

10

9.2

3

9.4

6

9.1

1

9.1

 Sterile

12

11

4

12.5

8

12.1

0

0

 Menopaused

35

32.1

6

18.8

22

33.3

7

63.6

0.078

 T2

84

77.1

23

71.9

55

83.3

6

54.5

 T3

25

22.9

9

28.1

11

16.7

5

45.5

0.048

 N0

50

45.9

9

28.1

36

54.5

5

45.5

 N1

59

54.1

23

71.9

30

45.5

6

54.5

0.745

 M0

105

96.3

31

96.9

63

95.5

11

100

 Mx

4

3.7

1

3.1

3

4.5

0

0

0.36

 I

1

0.9

1

3.1

0

0

0

0

 II

50

45.9

11

34.4

33

50

6

54.5

 III

56

51.4

19

59.4

32

48.5

5

45.5

 Unknown

2

1.8

1

3.1

1

1.5

0

0

 Overexpressed

106

97.2

32

100

63

95.5

11

100

 Non-determined

3

2.8

0

0

3

4.5

0

0

 Docetaxel + Trastuzumab + Bevacizumab

35

32.1

7

21.9

23

34.8

5

45.5

 Docetaxel + Trastuzumab

74

67.9

25

78.1

43

65.2

6

54.5